HB8160, the Premenstrual Dysphoric Disorder Awareness and Research Act of 2026, would direct the Department of Health and Human Services, primarily through NIH and HRSA, to expand federal research, education, and training related to Premenstrual Dysphoric Disorder (PMDD). The bill defines PMDD as a severe, chronic condition affecting an estimated 5 to 8 percent of women and people assigned female at birth of reproductive age, and states that it is often underdiagnosed, underresearched, and stigmatized. It emphasizes the need for better understanding of causes, risk factors, diagnosis, and treatment, as well as improved public and provider awareness.
The bill would authorize federal research efforts on PMDD, including clinical trials for improved treatments and data collection on prevalence, incidence, workforce and economic impacts, and barriers to diagnosis and treatment. It also requires attention to diverse racial, ethnic, and socioeconomic populations in research. In addition, it would create a public health awareness campaign, develop continuing medical education materials for providers, and award grants to eligible schools, hospitals, residency programs, and related training entities to expand clinical training on PMDD and related women’s health issues, including perimenopause and menopause.
In terms of state and federal policy impact, the bill does not directly amend state law, but it would expand federal public health and medical education activities and could influence clinical practice, research priorities, and access to care nationwide. It would also require HHS to report to Congress within two years on progress in research, awareness, and access to diagnosis and treatment. The bill authorizes such sums as necessary for multiple fiscal years to carry out its provisions, but it does not specify a funding amount.
The overall sentiment reflected in the bill text is strongly supportive of increased recognition and treatment of PMDD. The findings frame PMDD as a serious women’s health issue that has been neglected and stigmatized, and the bill’s structure is aimed at reducing that gap through research, education, and workforce training. No committee transcript or vote record is available, so there is no recorded opposition or debate in the provided materials.
Because no committee discussion or votes are included, there are no identified points of contention from the legislative record provided. Potential areas that could draw scrutiny in future consideration include the scope of federal spending, the emphasis on a condition affecting a specific population, and how training and awareness programs would be implemented and evaluated. However, based on the available text, the bill appears noncontroversial and focused on public health research and provider education.
HB8160 would expand federal responsibilities under the Public Health Service framework by directing HHS, NIH, and HRSA to conduct PMDD research, collect and publish data, run awareness campaigns, develop provider education materials, and award training grants. It would not directly change state statutes, but it could affect health care delivery, medical training, and diagnostic practices across states by increasing federal attention and resources for PMDD and related mid-life women’s health conditions.
The bill’s tone and findings are strongly supportive of action on PMDD, presenting the condition as serious, underdiagnosed, and stigmatized, with a clear need for more research and education. No votes or committee remarks are provided, so there is no evidence of opposition or divided sentiment in the record supplied. The available context suggests a generally favorable, public-health-oriented reception.
No specific contention appears in the provided record because there are no committee transcripts or votes. If concerns arise during consideration, they would likely center on federal spending levels, the breadth of the research and training mandate, and implementation details for HHS grant and awareness programs. The bill itself, however, is framed as a targeted health research and education measure rather than a controversial regulatory change.